Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 12;3(2):184-192.
doi: 10.1002/rth2.12195. eCollection 2019 Apr.

Hemophilia trials in the twenty-first century: Defining patient important outcomes

Barbara A Konkle  1   2 , Mark Skinner  3   4 , Alfonso Iorio  4   5
Affiliations
Review

Hemophilia trials in the twenty-first century: Defining patient important outcomes

Barbara A Konkle et al. Res Pract Thromb Haemost. .

Abstract

Treatment for hemophilia has advanced dramatically over the past 5 decades. Success of prophylactic therapy in preventing bleeding and decreasing associated complications has established a new standard of care. However, with the advent of gene therapy and treatments that effectively mimic sustained coagulation factor replacement, outcome measures that worked well for assessing factor replacement therapies in past clinical trials need to be reassessed. In addition, while therapies have advanced, so has the science of outcome assessment, including recognition of the importance of patient important and patient reported outcomes. This manuscript reviews strengths and limitations of outcome measures used in hemophilia from both a provider and patient perspective.

Keywords: bleeding; coagulation factor; gene therapy; hemophilia; outcomes research.

PubMed Disclaimer

References

    1. Hoag S, Johnson FF, Robinson JA, Aggeler PM. Treatment of hemophilia B with a new clotting factor concentrate. N Engl J Med. 1969;280:581–6. - PubMed
    1. Dallman PR, Pool JG. Treatment of hemophilia with factor eight concentrates. N Engl J Med. 1968;278:199–202. - PubMed
    1. Morfini M, Coppola A, Franchini M, Di Minno G. Clinical use of factor VIII and factor IX concentrates. Blood Transfus. 2013;11:S55–63. - PMC - PubMed
    1. White GC, Courter S, Bray GL, Lee M, Gomperts ED, White G, et al. A multicenter study of recombinant factor VIII (Recombinate(TM)) in previously treated patients with hemophilia A. Thromb Haemost. 1997;77:660–7. - PubMed
    1. Lusher JM. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost. 2002;28:273–6. - PubMed